Lanean...
Are cystic fibrosis mutation carriers a potentially highly vulnerable group to COVID‐19?
Undoubtedly, the new SARS‐CoV‐2 virus poses a grave health threat, plaguing the health and socio‐economic sectors. COVID‐19 disease must be treated quickly and effectively as soon as possible. The main axes in this direction are establishing vaccines, drugs, diagnostic tests, as well as identifying...
Gorde:
| Argitaratua izan da: | J Cell Mol Med |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley and Sons Inc.
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7675715/ https://ncbi.nlm.nih.gov/pubmed/33009727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.15941 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|